[1]D. Cavanagh, Coronavirus avian infectious bronchitis virus, Vet. Res. 38 (2007) 281–297. https://doi.org/10.1051/vetres:2006055.
[2]S. R. Weiss, J. L. Leibowitz, Coronavirus pathogenesis, in: Adv. Virus Res., Academic Press Inc., 2011: pp. 85–164. https://doi.org/10.1016/B978–0–12–385885–6.00009–2.
[3]Y. Lim, Y. Ng, J. Tam, D. Liu, Human Coronaviruses: A Review of Virus–Host Interactions, Diseases. 4 (2016) 26. https://doi.org/10.3390/diseases4030026.
[4]K. Dhama, R. V. S. Pawaiya, S. Chakraborty, R. Tiwari, M. Saminathan, A. K. Yerma, Coronavirus infection in equines: A review, Asian J. Anim. Vet. Adv. 9 (2014) 164–176. https://doi.org/10.3923/ajava.2014.164.176.
[5]J. Cui, F. Li, Z. L. Shi, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17 (2019) 181–192. https://doi.org/10.1038/s41579–018–0118–9.
[6]WHO | Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, WHO. (2015).
[7]WHO | Middle East respiratory syndrome coronavirus (MERS-CoV), (n.d.). https://www.who.int/emergencies/mers-cov/en/ (accessed April 17, 2020).
[8]J. F.-W. Chan, K.-H. Kok, Z. Zhu, H. Chu, K. K.-W. To, S. Yuan, K.-Y. Yuen, Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan, Emerg. Microbes Infect. 9 (2020) 221–236. https://doi.org/10.1080/22221751.2020.1719902.
[9]D. S. Hui, E. I Azhar, T. A. Madani, F. Ntoumi, R. Kock, O. Dar, G. Ippolito, T. D. Mchugh, Z. A. Memish, C. Drosten, A. Zumla, E. Petersen, The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis. 91 (2020) 264–266. https://doi.org/10.1016/j.ijid.2020.01.009.
[10]C. C. Lai, T. P. Shih, W. C. Ko, H. J. Tang, P. R. Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV–2) and coronavirus disease–2019 (COVID–19): The epidemic and the challenges, Int. J. Antimicrob. Agents. 55 (2020) 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924.
[11]N. Oliver, X. Barber, K. Roomp, K. Roomp, The Covid19Impact Survey: Assessing the Pulse of the COVID–19 Pandemic in Spain via 24 questions, (2020).
[12]S. P. Adhikari, S. Meng, Y. J. Wu, Y. P. Mao, R. X. Ye, Q. Z. Wang, C. Sun, S. Sylvia, S. Rozelle, H. Raat, H. Zhou, Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID–19) during the early outbreak period: A scoping review, Infect. Dis. Poverty. 9 (2020) 1–12. https://doi.org/10.1186/s40249–020–00646-x.
[13]S. Sarvagalla, S. B. Syed, M. S. Coumar, An Overview of Computational Methods, Tools, Servers, and Databases for Drug Repurposing, in: Silico Drug Des., Elsevier, 2019: pp. 743–780. https://doi.org/10.1016/b978–0–12–816125–8.00025–0.
[14]H. Hadni, M. Mazigh, M. Elhallaoui, QSAR and Molecular docking studies of 4-anilinoquinoline- triazine hybrids as pf-DHFR inhibitors, 8 (2019) 84–93.
[15]H. Hadni, M. Elhallaoui, Molecular docking and QSAR studies for modeling the antimalarial activity of hybrids 4-anilinoquinoline-triazines derivatives with the wild-type and mutant receptor pf-DHFR, Heliyon. 5 (2019) e02357. https://doi.org/10.1016/j.heliyon.2019.e02357.
[16] hanine hadni, menana elhallaoui, 2D and 3D-QSAR, molecular docking and ADMET properties in silico studies of azaaurones as antimalarial agents, New J. Chem. (2020). https://doi.org/10.1039/c9nj05767f.
[17]H. Hadni, M. Elhallaoui, 3D-QSAR, docking and ADMET properties of aurone analogues as antimalarial agents, Heliyon. 6 (2020) e03580. https://doi.org/10.1016/j.heliyon.2020.e03580.
[18]M. D. Hastings, C. H. Sibley, Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax, Proc. Natl. Acad. Sci. 99 (2002) 13137–13141. https://doi.org/10.1073/pnas.182295999.
[19]H. Hadni, M. Mazigh, E. Charif, A. Bouayad, M. Elhallaoui, Molecular Modeling of Antimalarial Agents by 3D-QSAR Study and Molecular Docking of Two Hybrids 4-Aminoquinoline–1,3,5-triazine and 4-Aminoquinoline-oxalamide Derivatives with the Receptor Protein in Its Both Wild and Mutant Types, Biochem. Res. Int. 2018 (2018) 1–15. https://doi.org/10.1155/2018/8639173.
[20]F. W. Muregi, A. Ishih, Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design, Drug Dev. Res. 71 (2009) n/a-n/a. https://doi.org/10.1002/ddr.20345.
[21]P. Gautret, J.-C. Lagier, P. Parola, V. T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V. E. Vieira, H. T. Dupont, S. Honoré, P. Colson, E. Chabrière, B. La Scola, J.-M. Rolain, P. Brouqui, D. Raoult, Hydroxychloroquine and azithromycin as a treatment of COVID–19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents. (2020) 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.
[22]J. Gabriels, M. Saleh, D. Chang, L. M. Epstein, Inpatient Use of Mobile Continuous Telemetry for COVID–19 Patients Treated with Hydroxychloroquine and Azithromycin, Hear. Case Reports. 0 (2020). https://doi.org/10.1016/j.hrcr.2020.03.017.
[23]A. K. Singh, A. Singh, A. Shaikh, R. Singh, A. Misra, Chloroquine and hydroxychloroquine in the treatment of COVID–19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries, Diabetes Metab. Syndr. Clin. Res. Rev. 14 (2020) 241–246. https://doi.org/10.1016/j.dsx.2020.03.011.
[24]Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, J. Yu, L. Wang, K. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao, H. Yang, Structure of Mpro from COVID–19 virus and discovery of its inhibitors, BioRxiv. (2020) 2020.02.26.964882. https://doi.org/10.1101/2020.02.26.964882.
[25]A. Kouranov, L. Xie, J. de la Cruz, L. Chen, J. Westbrook, P. E. Bourne, H. M. Berman, The RCSB PDB information portal for structural genomics, Nucleic Acids Res. 34 (2006) D302–D305. https://doi.org/10.1093/nar/gkj120.
[26]D. S. BIOvIA, Discovery studio modeling environment., San Diego, Dassault Syst. Release, 4. (2015). https://doi.org/https://doi.org/10.11436/mssj.17.98.
[27]G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, A. J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem. 30 (2009) 2785–2791. https://doi.org/10.1002/jcc.21256.
[28]G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, A. J. Olson, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, J. Comput. Chem. 19 (1998) 1639–1662. https://doi.org/10.1002/(SICI)1096–987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B.
[29]L. L. G. Ferreira, A.D. Andricopulo, ADMET modeling approaches in drug discovery, Drug Discov. Today. 24 (2019) 1157–1165. https://doi.org/10.1016/j.drudis.2019.03.015.
[30]C. Y. Jia, J. Y. Li, G. F. Hao, G. F. Yang, A drug-likeness toolbox facilitates ADMET study in drug discovery, Drug Discov. Today. 25 (2020) 248–258. https://doi.org/10.1016/j.drudis.2019.10.014.
[31]D. E. V. Pires, T. L. Blundell, D. B. Ascher, pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures, J. Med. Chem. 58 (2015) 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104.
[32]A. Daina, O. Michielin, V. Zoete, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (2017). https://doi.org/10.1038/srep42717.
[33]W. J. Egan, K. M. Merz, J. J. Baldwin, Prediction of drug absorption using multivariate statistics, J. Med. Chem. 43 (2000) 3867–3877. https://doi.org/10.1021/jm000292e.
[34]D. E. Clark, In silico prediction of blood–brain barrier permeation, Drug Discov. Today. 8 (2003) 927–933. https://doi.org/10.1016/S1359–6446(03)02827–7.